The training material includes a range of new downloadable marketing resources for vets and SQPs to help maintain communications with their farmer customer base while face-to-face contact opportunities are restricted. They include a newsletter and social media and farmer engagement tools for various dairy, beef and sheep disease management issues.
Vets can also access new BRD management content highlighting the benefit of immunity-led disease prevention and ultrasound scanning of calf lungs. You can also view a range of practical ‘how to’ videos, as well as five different webinar recordings explaining ways to collaborate more effectively with farmers over youngstock rearing issues. The content is based on implementing MSD Animal Health’s versatile calf health checklist engagement tool, which facilitates an audit-based approach to assessing and improving current on-farm management practices.
MSD says it has another two webinars in the pipeline, which will be released in the weeks ahead: ‘Immunology’ with Professor James Roth and ‘Salmonella’ with Katrina Henderson from SAC.
To access all the training content, visit: https://www.msd-animal-health-hub.co.uk
MSD Animal Health (Merck in the US and Canada), has launched Finadyne (flunixin), the NSAID for cattle, as a pour on.
According to the company, Finadyne Transdermal is the world's first non-parasiticide cattle product to be made available as a pour-on.
Dr. Martin Behr, technical manager at MSD Animal Health said: “Finadyne Transdermal is uniquely designed for rapid absorption into the bloodstream and its antipyretic effect has been demonstrated as early as two hours after treatment. This is because innovative penetration enhancers are included in the formulation to improve the absorption of the active ingredient flunixin through the skin.”
The new product comes in pre-calibrated packaging and uses a bottle designed for easy application along an animal’s back.
Dr. Behr added: “It’s much simpler for farmers to treat cattle in this way – as opposed to administering an injection, which can also mean needle-site lesions that can reduce the value of a carcass or compromise hide quality.
“The time taken to handle and treat animals will be much reduced with a transdermal NSAID. There will also be a saving on syringes and needles.”
Finadyne Transdermal (POM-V) is available now from veterinary wholesalers. Further information is available from the MSD Animal Health veterinary support group on 01908 685685.
The responsible use of antibiotics termed critically important is an important strand in the UK policy to fight antibiotic resistance development.
However, NOAH says there is much confusion about which antibiotics should be considered within this group, with different organisations referring to different classes.
Donal Murphy, Head of Technical and Regulatory Affairs at NOAH said: "NOAH believes the classification and use of antibiotics in veterinary medicine should be driven and guided by the regulators, who are independent and make science based decisions and recommendations.
"Of course, all classes of antibiotics, whether critically important or not, should be used responsibly and guided by the principle outlined by the Responsible Use of Medicines in Agriculture Alliance (RUMA) who state they should be used 'as little as possible but as much as necessary'. The use of these important products in this manner can ensure that the availability and efficacy of antibiotics can be maintained to ensure animal health and welfare in the future."
You can download the briefing document here.
Research on ovine parasite Toxoplasma gondii, carried out at the University of Salford, could have a significant economic impact on the sheep farming industry - potentially saving the lives of 5% of the UK lamb population.
Postgraduate student Emma Morley has been working as part of a large research team, looking at the importance of transmission routes of T. gondii (the cause of the disease toxoplasmosis) within different mammalian groups.
A scholarship from the Perry Foundation, which funds research benefiting the farming industry, allowed Emma to launch her own study at the School of Environment & Life Sciences.
Salford parasitologist Professor Geoff Hide said: "Emma's research may have some significant impacts on sheep farming. Nearly 5% of lambs are lost to Toxoplasma in the UK so it's of major economic importance as well as an important animal welfare issue."
He said that one of the key things Emma's research has shown is that the advice currently given to farmers may be causing an increase in the level of the disease rather than controlling it. "Farmers are advised to breed from ewes that have lost lambs to Toxoplasma but Emma's results show that what farmers should be doing is breeding from ewes that do not have the parasite," he said.
Dairy vets will soon be receiving a DVD highlighting the economic losses due to coccidiosis in cattle, from Janssen Animal Health.
According to the company, coccidiosis is a major cause of scouring and poor growth rates in calves yet recent findings have demonstrated that a massive 61 per cent of the economic loss occurs in sub-clinically infected calves that are not showing any obvious clinical signs. Treated calves have been shown to put on 20 per cent more weight than untreated calves1. Coccidiosis infects between 16 and 27 per cent of adult cattle who act as reservoirs of the disease2,3,4,5. This means that most calves are likely to become exposed to the infectious form of the parasite. After the age of 6 months the majority of calves acquire immunity but if they are exposed to a massive challenge before that time due to large numbers of the coccidial oocysts or due to a stress factor, sub-clinical or clinical disease occurs.
The DVD describes the challenges involved in diagnosing coccidiosis and how to interpret faecal oocyst counts, as well as some of the characteristics of sub-clinical infection in calves. The benefits of metaphylactic and preventative approaches to treatment with Vecoxan®, the only anticoccidial drench licensed for beef and dairy cattle at any age, indoors and out, are discussed.
Nigel Underwood from Janssen Animal Health said: "The diagnosis of non-specific scour is problematic at best but it is important that vets have coccidiosis at front of mind when considering the differential diagnosis. Prompt treatment of the whole batch of calves can stop the disease in its tracks and does not interfere with the development of future immunity. We hope this DVD will provide an update on the latest thinking and help increase recognition of this disease."
The DVD will be sent out in February and any vet with an interest in the disease who does not received one before the end of the month should call Janssen on 01494 567555 to request a copy.
Further information is available from Janssen Animal Health, 50-100 Holmers Farm Way, High Wycombe, Bucks, HP12 4EG Tel 01494 567555 Fax 01494 567556 Email: ahealth@jacgb.jnj.com
References
The announcement came hot on the heels of announcements from Ceva and Boehringer that they too had vaccines in the pipeline.
Syvazul BTV3 is licensed to reduce viraemia, prevent mortality and reduce clinical signs and lesions in sheep and for the active immunisation against bluetongue virus serotype 3 in cattle.
Like all vaccines currently available for this serotype, the vaccine will not prevent infection and vaccinated animals will still be subject to bluetongue movement controls and trade restrictions currently in place.
Administered as a single 2ml dose subcutaneously in sheep and as two 4ml intramuscular doses 3 weeks apart in cattle, Syvazul BTV3 contains inactivated Bluetongue virus, serotype 3 (BTV-3), strain BTV-3/NET2023.
The vaccine is licenced for use during pregnancy and lactation in both sheep and cattle.
The onset of immunity is 28 days after the primary vaccine in sheep. A single booster revaccination dose of 2ml for sheep and 4ml for cattle is recommended after 12 months.
Presented in two pack sizes, 80ml and 200ml, Syvazul BTV3 vaccine has a shelf life of 2 years from manufacture and a broach life of 10 hours.
Licensing for use will be geographic, based upon high risk counties or by specific licence from the APHA.
The recall was initiated because a visual inspection confirmed the possibility of particulate contamination which is not acceptable for an intravenous use preparation.
The recall is for the following batches only:
108AB Expiry 12/01/2023113H Expiry 16/03/2023
Ceva Animal Health Ltd is contacting veterinary surgeons, retailers and wholesale dealers to examine inventory and quarantine products subject to the recall.
For further information, contact Peter Kyte Business Unit Manager on +44 1494 781510.
Bovalto Respi 3 contains strains of parainfluenza virus 3, bovine respiratory syncytial virus and Mannheimia haemolytica serotype A1.
Bovalto Respi 4 combines the three pathogens in Bovalto Respi 3, with the addition of bovine viral diarrhoea virus.
According to the company, calf pneumonia costs are around £43/€49* per dairy calf and £82/€93* per suckler calf1.
Boehringer’s vet adviser Ailsa Milnes said: "The majority of these costs are made up of mortality, slower growth rates and reduced lifetime performance.
"It is worth remembering that calf pneumonia can cause irreversible damage to the lungs which means that, even if the animal recovers, its lifetime performance suffers and it will be more susceptible to disease in the future.
"Bovalto Respi 3 and Bovalto Respi 4 are the only vaccines available to demonstrate six months of immunity by challenge for all pathogens, and calves develop protective immunity three weeks after completion of the primary vaccination course.
"Now, with the added flexibility of being able to administer the vaccines to pregnant cattle, the overall level of respiratory disease in a herd will hopefully fall and overall health status improve as a result."
Reference
A Government decision not to embark on a badger cull in England, as reported today, will be the correct one for both badgers and cattle, says the RSPCA.
"This would be the right decision based on compelling evidence, particularly because the most authoritative scientific research ever undertaken on the subject recommended against badger culling as an effective way of controlling TB," said Dr Rob Atkinson, RSPCA Head of Wildlife Science.
"Evidence indicates that the vast majority of badgers are not infected with TB. Our opposition to a badger cull is based on solid science not sentiment. The RSPCA cares as much about cattle welfare as badgers. We are keen to work with farmers and governments to find positive solutions to the challenge of TB in cattle."
The Badger Trust's legal challenge to Defra's plans for targeted badger cull pilots has failed in the High Court on all three grounds.
Whilst the RSPCA has expressed its disappointment, the British Veterinary Association and British Cattle Veterinary Association have welcomed the judgement.
BVA President Carl Padgett said: "We are pleased that the High Court has ruled Defra's policy lawful and that the pilot badger culls can now go ahead.
"The BVA and BCVA believe that the government's approach has been robust and justifiable as it is based on our current scientific knowledge.
"Bovine TB is a devastating disease and we must tackle the disease in wildlife alongside cattle controls if we are to get on top of it."
David Bowles, the RSPCA's Director of Communications, said: "We are bitterly disappointed that the UK Government in England is ploughing on with plans to kill badgers but the fight is not over yet.
"We believe culling is not a long-term, sustainable solution and will be of little help in reducing the disease - perhaps even making things worse in some areas. It will wipe out huge numbers of this much-loved species, virtually eliminating badgers from these areas, including many animals which are healthy.
"It is not as if there aren't alternatives to a cull. Vaccination could be a more effective and sustainable way of dealing with the disease, and one which does not involve killing most of the badger population in very large areas of the countryside."
The webinar, titled: ‘When the coughing won’t stop…. what to do when standard BRD treatment protocols aren’t getting to the bottom of it’, aims help vets manage complex outbreaks that happen despite best practice management and treatment protocols.
The full programme includes:
The event is being held live so you can submit questions to the speakers, but the session will be recorded, so it can be watched again later.
Attendees will receive a certificate for one hour of CPD and the link to the recorded webinar.
To register, email the event team by 27 November 2020 at brdwebinar-group@ceva.com. In the email, please give your name and the email address to which you would like the registration link sent.
The idea for an interactive vaccination calendar was in fact first developed two years ago by Jon Reader MRCVS (pictured right) from Synergy Farm Health. With input and funding from Boehringer, it has now been developed into an online tool which highlights times when animals may be at risk if immunity has waned, without sufficient boosting of immunity by vaccination.
The transmission of BVD is complex and protecting the foetus from the virus is at the heart of any control programme. The virus is passed from dam to foetus and, if this occurs in the first third of pregnancy and the foetus goes to term, a persistently infected (PI) calf will be born. These will then go on to shed virus throughout their lives, so infecting herdmates and the next generation of calves.
Jon said: "The timing of when a vaccine is given is critical to the development of an immune response, which will protect the unborn foetus.
"Working out when you want the dam to calve and then calculating back shows when either a primary course of BVD vaccine or a booster should be given but, get this wrong and you will end up with what is known as an 'immunity gap'.
"It is vital that both heifers and cows have maximum protection during the breeding period and in early pregnancy."
Boehringer says heifers must be fully protected before being served for the first time, and cows must have had immunity boosted before they are pregnant again. However, far too often heifers are adequately protected following an initial booster but given their age and date of service, do not receive further protection until they enter the adult herd.
Jon said: "If heifers calve just after the herd booster, then there is a very real possibility that they will go for two years without a booster, and be severely exposed when they become pregnant as a first lactation heifer."
"This is termed the immunity gap; a period when the animal is not protected from the virus at all. The aim should be to eliminate this period completely, so that there is no immunity gap."
Matt Yarnall from Boehringer said: "Each BVD vaccine has its own timing protocol stating when the primary course should be given, as well as subsequent booster timing and when cows should be served. Moreover, some of these are not straightforward to follow, especially for year-round calving herds."
"Anyone using the Bovela vaccine has peace of mind that the one dose primary course combined with flexible booster regime and 12 months’ proven duration of immunity minimises the immunity gap."
For more information, visit: makebvdhistory.co.uk.
Agrimin has announced the launch of a new range of boluses for sheep and cattle that use 'eroding technology' to deliver a sustained supply of three trace elements for up to 180 days:
According to Agrimin, each bolus is designed to provide the full daily requirement of cobalt and selenium and the largest available daily supply of iodine to both cattle and sheep. The boluses do not contain any copper, an element known to cause issues in certain parts of the country, in closely managed dairy cows or in continental sheep breeds.
Each bolus is made up of two parts, held together by a soluble wrapper. After administration, the wrapper dissolves and the two halves remain in the reticulum where they erode and dissolve. This process delivers a continuous and regular supply of nutrients to the animal.
Agrimin's Dr Jamie Bennison said that the new range has been extensively trialled in New Zealand and at Glasgow Veterinary School: "Trials have confirmed a sustained release profile which ensures that iodine, selenium and cobalt levels are maintained throughout the active life of the bolus. In farm trials this has translated into higher levels of the elements in blood samples and improved animal productivity."
Treatment is one bolus per animal (48g for sheep; 160g for cattle) administered with an Agrimin bolus gun. One bolus is sufficient to meet the animal's full daily requirement for 180 days.
For more information about the 24•7 Iodine•Selenium•Cobalt range of cattle and sheep boluses, please visit http://www.agrimin.com/ or call 01652 688046.
The British Pig Executive (BPEX) is urging veterinary surgeons to promote a 'top five' of farm services which will be available to pig farmers that sign up to BPEX's new national pig health scheme.
The Pig Health Improvement Project (PHIP) became a national scheme in July following regional projects in Yorkshire, Humberside, East Anglia and the East Midlands. BPEX says it is now stepping up a gear as much of the infrastructure has been put in place and clear membership benefits are available.
BPEX's Vet Project Manager Helen Clarke said: "The PHIP takes a collaborative, action-orientated approach to reducing the incidence of disease in pig herds to ensure the long-term sustainability of pig farming. The role of vets in delivering the scheme is key.
"We need to achieve a high level of uptake - and are looking to achieve sign-up from farms that together represent at least 90% of sows nationally. And that's why we are keen for farmers to take advantage of these five services that deliver benefits at farm level."
The services consist of:
Sign-up is free for producers. To find out how vets can support the scheme, visit http://www.pighealth.org.uk/ and contact BPEX on 02476 478877.
For the randomised controlled trial, 528 dairy heifers were monitored for 34 months to investigate the effects of routine treatment with a NSAID at calving and during treatment for lameness, on the future probability of lameness and culling.
The cows were exposed to normal farm conditions and were split into four groups:
During the study, the probability of lameness was assessed by a lameness outcome score collected every 14 days.
Data on culling was also extracted from farm records.
438 animals were included in the final analysis which revealed that treating a cohort of cows following the group three protocol led to an absolute reduction in lameness of approximately 10% and severe lameness of 3%, compared with animals treated in accordance with conventional best practice (group one).
James Wilson BSc(Hons) PhD, foot health consultant and lead researcher on the trial, said: “It appears that through giving heifers a NSAID at critical time points, we have imparted a substantial, long-lasting benefit to them.
"When freshly calved heifers enter the herd for the first time, we understand that they are (typically) naïve to lameness and have good hoof health.
"By utilising NSAIDs strategically, we believe that we have preserved the functionality of the foot, thereby reducing the risk of lameness.
"This is a highly efficacious, cost-effective means of managing lameness on farm.”
Herd Health Consultancy says that in dairy cows, it is advisable to consider using a zero milk-withhold NSAID which is fully licensed to treat lameness in cattle to avoid any need to discard milk, however no NSAID is currently licensed in the UK to treat the pain associated with calving, so careful advice should be given to farmers based on the farm type and production methods.
https://doi.org/10.3168/jds.2021-21329
CEVA Animal Health has published an information booklet on Q Fever to help broaden awareness and understanding of the disease.
Q Fever is an emerging, worldwide disease that affects goats, cattle and sheep as well as humans. It is caused by the bacterium Coxiella burnetii and can induce late abortions, metritis, fertility problems, mastitis and low vitality in neonates born from carrier animals.
The new booklet explains how the disease is transmitted, the symptoms, diagnosis and how it can be managed and prevented. CEVA already have expertise in the treatment of diseases caused by Coxiella burnetii and have developed a vaccine that has been used under temporary license to control outbreaks in France and the Netherlands.
To obtain a copy of the booklet please contact CEVA Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG. The proceedings from CEVA's recent symposium on Q fever, held in Marseilles in December 2009 are also available on request.
The Veterinary Development Council (VDC) is conducting a survey to investigate the role of paraprofessionals and technicians in veterinary practice, and is asking vets in large animal, equine, and mixed practices to complete a short survey.
The VDC says that information from the survey will help inform discussions on the regulation of technicians.
The survey will take between 5 and 10 minutes to complete and can be found on the BVA website at www.bva.co.uk/vdc. The BVA has also emailed the survey directly to practices.
The survey has been devised by the VDC working group looking at the role of the veterinary-led team, chaired by BVA Past President Professor Bill Reilly. This is one of three working groups that will report to the VDC:
Professor Reilly said: "The relationship between veterinary surgeons and technicians is vital but it varies from practice to practice.
"The working group on the role of the veterinary-led team aims to take a snapshot of how services, such as artificial insemination and foot trimming, are currently delivered, and gauge how veterinary surgeons feel about other services being delivered by non-veterinarians in the future.
"I hope veterinary surgeons in large, mixed and equine practice will take 10 minutes to complete our survey to help us map the current use of technicians in veterinary practice and help shape our future discussions."
There had already been a gap in supply of the vaccine between June and August due to a batch being out of specification.
The company says it submitted an Out of Specification request to release the vaccine but was unsuccessful.
The next delivery of vaccine was expected at the end of August, however this has unfortunately been delayed until October, and there is no certainty of this delivery.
Ceva says it deeply regrets the inconvenience caused to sheep farmers this year.
Roy Geary, Vice President for Northern Europe (including the UK) at Ceva Animal Health, said: “The manufacturing of vaccines is a complex process that involves stringent quality control measures and adherence to regulatory guidelines.
"There have been unforeseen manufacturing issues at our production facilities, which have temporarily affected the ability to meet the demands of the UK sheep market within the main seasonal vaccination period for EAE.
"As a responsible provider, we are actively addressing these issues to minimise the impact on customers.”
“We are recommending that vets and farmers follow the advice published on 24th July 2024 from the Sheep Vet Society and Sheep Antibiotic Guardian Group (SAGG).”
https://sheepvetsoc.org.uk/news/sheep-veterinary-society-svs-and-sheep-antibiotic-guardian-group-sagg-advice-for-when-an-enzootic-abortion-eae-vaccine-is-unavailable.
Colivet® solution, one of CEVA Animal Health’s range of 3 soluble antimicrobials for pigs has been renamed Coliscour®.
Phil McGuire, CEVA’s business unit manager, explains the reasoning behind the name change: “We simply felt that the easiest way to avoid confusion between our product and a totally different non-prescription product of a similar name was to give ours a new name that also reflects its use, hence Coliscour®.”
This latest incarnation of the FECPAKG2 is now a battery-powered and wi-fi enabled. This means it can pair with smartphones, tablets and laptops, allowing samples to be uploaded, analysed and results received, virtually anywhere.
Tabitha Allen from Techion said: "The technology allows internet connected and image-based FEC testing to be carried out literally on the job.
"While the current system is able to return results rapidly, samples need to be uploaded via a computer. The upgrade will therefore give users more flexibility, allowing samples to be processed away from the office."
"Samples are then analysed by trained online technicians so we can confidently provide accurate results, which can then help farmers make informed decisions when it comes to worming.
"The new upgrade now includes a digital microscope that enhances image quality further, making it quicker and easier than ever before to provide these accurate results.
For more information, visit: www.techiongroup.com or ring: 01970 821 918
Metacam 40 mg/ml solution for injection for cattle and horses contains 40 mg/ml of meloxicam, and is available in either 50 ml or 100 ml presentations. It is approved for subcutaneous or intravenous use in cattle, and intravenous use in horses.
Boehringer says the introduction comes on the back of a recent large-scale landmark study that found adding Metacam to standard antibiotic therapy for mastitis resulted in a greater first-service conception rate, fewer inseminations required to conceive and a higher probability of pregnancy by 120 days post-calving when compared to cows receiving antibiotic therapy alone1.
Boehringer Ingelheim’s technical manager Kath Aplin said: "By reducing the pain and inflammation caused by mastitis and other conditions, the use of Metacam 40 can result in improvements in cattle health and welfare, and may help limit any reduction in feed intakes. This is central to efficient herd management and productivity."
The company adds that new Metacam 40 mg/ml formulation offers a lower volume dose compared to the existing 20 mg/ml presentation, giving vets more flexibility in their use of Metacam.
Prevexxion RN is composed of a serotype-1 construct vaccine which Boehringer says offers a unique balance between safety and efficacy against the most virulent types of Marek’s disease virus strains.
Prevexxion RN+HVT+IBD is a solution combining Prevexxion RN and Vaxxitek HVT+IBD in one ampoule. It is designed to meet the needs of customers in long-life bird segments with protection from the hatchery.
Prevexxion RN vaccines are available in ampoules of 1000, 2000, and 4000 doses, frozen in liquid nitrogen.
Jerôme Baudon, Head of Poultry at Boehringer Ingelheim, said: “Our Prevexxion RN range provides value through innovation to Marek sensitive poultry producers looking for continuous live production productivity improvement and effective protection. Field and lab experiments conducted worldwide demonstrated its safety, efficacy and its strong, early, and long-lasting protection through the lifespan of the birds and against very virulent Marek’s disease challenge.
Prevexxion RN is the new golden standard for Marek's disease vaccination programs2”.
For more information, contact your Boehringer Ingelheim representative.